The biotech firm’s first-quarter GAAP EPS fell short of estimates by a penny, while cash reserves extend runway to late 2026.
Pyxis Oncology reported a first-quarter GAAP loss of $0.37 per share, missing analyst expectations by $0.01. The wider-than-anticipated loss reflects ongoing R&D and operational costs for the clinical-stage company.
Cash and cash equivalents, including restricted cash and short-term investments, totaled $42.5 million as of March 31, 2026. The company stated these funds are projected to sustain operations into the fourth quarter of 2026, aligning with prior guidance.
No immediate market reaction was disclosed in the release.